REFERENCES
- Kontoghiorghes GJ, Spyrou A, Kolnagou A. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption. Hemoglobin. 2010;34(3):251–264.
- Kontoghiorghes GJ. Chelators affecting iron absorption in mice. Arzneimittelforschung. 1990;40(12):1332–1335.
- Kontoghiorghes GJ. Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide. Hemoglobin. 2008;(32):608–615.
- Nick H, Wong A, Acklin P, ICL670A: preclinical profile. Adv Exp Med Biol. 2002;509:185–203.
- Cappellini MD, Cohen A, Piga A, A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood. 2006;107(9):3455–3462.
- Vichinsky E, Onyekwere O, Porter J, A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136(3):501–508.
- Fabio G, Minonzio F, Delbini P, Bianchi A, Cappellini MD. Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH). Blood. 2007;109(1):362–364.
- Olivieri NF, Koren G, Matsui D, Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood. 1992;79(10):2741–2748.
- Nielsen P, Fischer R, Buggisch P, Janka-Schaub G. Effective treatment of hereditary haemochromatosis with desferrioxamine in selected cases. Br J Haematol. 2003;123(5):952–953.
- Pootrakul P, Sirankapracha P, Sankote J, Clinical trial of deferiprone iron chelation therapy in β-thalassaemia/Haemoglobin E patients in Thailand. Br J Haematol. 2003;122(2):305–310.
- Phatak P, Brissot P, Wurster M, A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology. 2010; [Epub ahead of print] doi: 10.1002/hep.23879.
- Phatak PD, Brissot P, Bonkovsky H, A Phase I/II, open-label, dose-escalation trial of once-daily oral chelator deferasirox to treat iron overload in HFE-related hereditary hemochromatosis: final results of the core study. Blood. 2009;114(22):1514 (abstract).
- Kontoghiorghes GJ. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients. Hemoglobin. 2009;33(5):332–338.
- Pennell DJ, Porter JB, Cappellini MD, Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia. Blood. 2010;115(12):2364–2371.
- Kontoghiorghes GJ, Kolnagou A, Peng CT, Shah SV, Aessopos A. Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases. Expert Opin Drug Saf. 2010;9(2):201–206.
- Steinhauser S, Heinz U, Bartholoma M, Complex formation of ICL670 and related ligands with FeIII and FeII. Eur J Inorg Chem. 2004;21:4177–4192.
- Thalassaemia International Federation. Guidelines for the clinical management of thalassaemia, 2nd Revised Edition. http://www.thalassaemia.org.cy/pdf/Guidelines_2nd_revised_edition_EN.pdf2008.